Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04286607 · ClinicalTrials.gov registry record · Phase 3
Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis
A Phase 3 study, sponsored by Arcutis Biotherapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 333
- Enrollment target
NCT04286607 is a Phase 3 study that has completed, run by Arcutis Biotherapeutics. The registered enrollment target is 333 participants.
The verdict
NCT04286607, a Phase 3 study, has completed, sponsored by Arcutis Biotherapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 333 participants
- Enrollment target
Study Summary
This study will assess the safety and efficacy of ARQ-151 cream applied once a day for 24 weeks by subjects with chronic plaque psoriasis
Interventions
- DRUG Topical roflumilast
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 333 participants |
| Start Date | 2020-02-12 |
| Est. Completion | 2024-01-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04286607
The ClinicalTrials.gov registry entry for NCT04286607 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 333 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arcutis Biotherapeutics, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Topical roflumilast is the first listed.
NCT04286607 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04286607 about?
NCT04286607 is a clinical study titled "Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis". This study will assess the safety and efficacy of ARQ-151 cream applied once a day for 24 weeks by subjects with chronic plaque psoriasis
What is the current status of trial NCT04286607?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 333 participants. The study started on 2020-02-12. Estimated completion is 2024-01-22.
What interventions are being tested in trial NCT04286607?
The interventions under investigation include: Topical roflumilast (DRUG).
Who is sponsoring clinical trial NCT04286607?
This trial is sponsored by Arcutis Biotherapeutics, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.